Synthesis and SAR of highly potent and selective dopamine D3-receptor antagonists: Variations on the 1H-pyrimidin-2-one theme

https://doi.org/10.1016/j.bmcl.2005.12.079Get rights and content

Abstract

In our efforts to further pursue one of the most selective dopamine D3-receptor antagonists reported to date, we now describe the synthesis and SAR of novel and highly selective dopamine D3 antagonists based on a 1H-pyridin-2-one or on a urea scaffold. The most potent compounds exhibited Ki values toward the D3 receptor in the nano- to subnanomolar range and high selectivity versus the related D2 dopamine receptor. Thus, 1H-pyridin-2-one 7b displays oral bioavailability (F = 37%) as well as brain penetration (brain plasma ratio 3.7) in rat. Within the urea series, an excellent D3 versus D2 selectivity (>100-fold) could be achieved by removal of one NH group (compound 6), although bioavailability (rat) was suboptimal (F < 10%). These data significantly enhance our understanding of the D3 pharmacophore and are expected to lead to novel approaches for the treatment of schizophrenia.

Graphical abstract

Synthesis and SAR of highly potent and selective D3 antagonists based on a 1H-pyridin-2-one or on a urea scaffold are described. Thus, 7b displays oral bioavailability as well as brain penetration in rat. These data significantly enhance our understanding of the D3 pharmacophore and are expected to lead to novel approaches for the treatment of schizophrenia.

  1. Download : Download full-size image

Section snippets

Acknowledgments

We thank Stefan Maurus, Karlpeter Orth, Katerina Sarris, and Sonja Triebel for supporting chemical synthesis, our analytical department, Manfred Nebel, Heidrun Gärtner, and Beate Rauprich for assay development and screening, Sylvia Hellwig for the permeability measurements (Caco-2).

References and notes (14)

  • H. Geneste et al.

    Bioorg. Med. Chem. Lett.

    (2006)
  • H. Geneste et al.

    Bioorg. Med. Chem. Lett.

    (2006)
  • N.A. Bumagin et al.

    Tetrahedron

    (1997)
  • K. Wicke et al.

    Eur. J. Pharmacol.

    (2001)
  • Unger, L.; Ladona, F. J. G.; Wernet, W.; Sokoloff, P.; Wicke, K. M.; Gross, G. Poster, 32nd Annual Meeting of the...
  • A.J. Leo et al.

    Perspect. Drug Discovery Des.

    (2000)
There are more references available in the full text version of this article.

Cited by (0)

View full text